What do systematic reviews say?

Intervention not reported

• Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension 2015 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1007 participants
  Very low

Intervention not reported

• Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension 2015 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1412 participants
  Moderate

Community ambulation intervention vs other interventions

• Interventions for improving community ambulation in individuals with stroke 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 198 participants
  Low

Community ambulation intervention vs other interventions

• Interventions for improving community ambulation in individuals with stroke 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 45 participants
  Low

Community ambulation intervention vs other interventions

• Interventions for improving community ambulation in individuals with stroke 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 45 participants
  Low

Community ambulation intervention vs other interventions

• Interventions for improving community ambulation in individuals with stroke 2015 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 98 participants
  Low

Community ambulation intervention vs other interventions

• Interventions for improving community ambulation in individuals with stroke 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 55 participants
  Low

Community ambulation intervention vs other interventions

• Interventions for improving community ambulation in individuals with stroke 2015 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 97 participants
  Low

Angiotensin receptor blockers (ARBs) vs conventional therapy

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 110 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs conventional therapy

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Low

Angiotensin receptor blockers (ARBs) vs conventional therapy

Angiotensin receptor blockers (ARBs) showed no clear difference in adverse events (episodes of peritonitis) compared with conventional therapy (low certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 0.67 [0.18, 2.54]
  1 study · 34 participants
  Low

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Angiotensin‐converting enzyme inhibitors (ACEi) probably leads to lower anuria compared with conventional therapy (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 0.32 [0.11, 0.94]
  1 study · 60 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in mortality compared with conventional therapy (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.5 [0.27, 8.34]
  1 study · 60 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events compared with conventional therapy (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1 [0.37, 3.21]
  1 study · 60 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events (fatal) compared with conventional therapy (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1 [0.15, 6.64]
  1 study · 60 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events (non fatal) compared with conventional therapy (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1 [0.31, 3.27]
  1 study · 60 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) compared with conventional therapy (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.13 [0.47, 2.71]
  1 study · 60 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) ‐ treated with an… compared with conventional therapy (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.2 [0.41, 3.51]
  1 study · 60 participants
  Moderate

Angiotensin‐converting enzyme inhibitors vs conventional therapy

Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) ‐ not treated with an… compared with conventional therapy (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1 [0.22, 4.56]
  1 study · 60 participants
  Moderate

Angiotensin receptor blockers (ARBs) vs angiotensin‐converting enzyme inhibitors (ACEis)

Angiotensin receptor blockers (ARBs) showed no clear difference in anuria compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).

• Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in… 2014 · Cochrane Headline outcomes only
  RR 1.15 [0.41, 3.26]
  1 study · 60 participants
  Moderate